A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis

Natalizumab, an anti-alpha4 integrin antibody, significantly reduces the number of visibly enhancing multiple sclerosis (MS) lesions. In this substudy of a 2-year trial of natalizumab monotherapy versus placebo, contrast-enhanced imaging investigated for subtle blood brain barrier (BBB) leakage in r...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of neurology Ročník 254; číslo 3; s. 306 - 314
Hlavní autori:	Soon, Derek, Altmann, Daniel R., Fernando, Kryshani T.M., Giovannoni, Garin, Barkhof, Frederick, Polman, Chris H., O’Connor, Paul, Gray, Bruce, Panzara, Michael, Miller, David H.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin Springer 01.03.2007 Springer Nature B.V
Predmet:	Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Blood-Brain Barrier - drug effects Case-Control Studies Double-Blind Method Female Follow-Up Studies Gadolinium DTPA Humans Immunomodulators Magnetic Resonance Imaging - methods Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Natalizumab Neurology Pharmacology. Drug treatments Statistics, Nonparametric Multiple sclerosis Nervous system diseases Natalizumab Central nervous system disease Central nervous system Placebo Blood brain barrier Tysabri·BBB·MS Encephalon Inflammatory disease
ISSN:	0340-5354, 1432-1459
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!